Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Index funds vary in tax efficiency; choosing the right ones can lower taxable gains and boost after-tax returns. This guide covers tax-smart picks and strategies.
24,188 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
As AI pilots prove promising in tests, many companies stumble when expanding. Experts say governance, outcome clarity...
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...
A former Meta public policy director alleges the company spied on her for more than a year to suppress discussion of ...
Investors often wonder if a smaller company can replicate Berkshire Hathaway’s long-term success. This analysis looks...
AST SpaceMobile just completed a trio of successful BlueBird launches, yet spacemobile's stock down after the event. ...
Oklo is developing compact nuclear reactors geared for AI data centers. This article lays out a grounded five-year ro...
Palantir chief executive officer Alex Karp charges that frontier AI models are siphoning value from enterprises. The ...
A veteran market strategist argues Big Tech is underappreciated as earnings grow and capital spending remains durable...
Michael Burry has added a Micron short, expanding a wager that AI-driven chip stocks may soon pull back. The move com...
Patient investors who focus on durable competitive advantages can unlock meaningful returns. This article explains a ...
A historic heat dome pushed the PJM grid toward an all-time peak. This investing backdrop highlights four power stock...